Where does Moximed, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Moximed, Inc. ranks #8,252 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Moximed, Inc. hold?

Moximed, Inc. holds 39 US utility patents granted between 2015 and 2022, spanning 3 technology areas.

What is Moximed, Inc.'s Innovation Score?

Moximed, Inc. has an Innovation Score of 27.4 out of 100 (24th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Moximed, Inc. focus on?

Moximed, Inc.'s top technology area is A61B (DIAGNOSIS; SURGERY; Identification) with 39 patents, ranking #491 of 7,127 assignees active in that subclass. Grants appear in 3 CPC subclasses total.

Is Moximed, Inc.'s patent grant rate increasing or decreasing?

Moximed, Inc.'s recent grant velocity is -78% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Moximed, Inc.'s patents?

Moximed, Inc.'s patents average 13.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Moximed, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Moximed, Inc.

USPTO PatentsView assignee record - 39 granted patents across 3 technology areas, recorded in grant years 2015–2022. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Moximed ranks #8,252 of 49,997 tracked US assignees by granted-patent volume, with 39 patents across 3 technology areas.

#8,252
of 49,997 US assignees by volume: 24th percentile
by Innovation Score (27.4/100): 13.2
avg claims per patent: -78%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R8252 · US Corporation #8,252 · 39 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 39 grants
UPPER-Q #8,252/49,997
PHOTO-FINISH Mercari
CPC-NARROW A61B · 3 areas
INNOV-THIN 27.4/100
CLAIMS-RICH 13.2 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -78% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Mercari, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Moximed’s 27.4 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 12.7 pts (46%) Velocity 0.7 pts (3%) Breadth 6.1 pts (22%) Claim depth 7.9 pts (29%)

Qualcomm Incorporated · highest

85
Kverneland A/S · near

27
Zwilling J A Henckels · near

27
Codman Neuro… · near

27
Moximed · this assignee

27
InSyte Systems · near

27
3D Lighting… · lowest

7

What this shows Moximed's Innovation Score is 27.4/100 (24th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Moximed?

Each dot is one of Moximed’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Moximed’s own 13.2 claims/patent is at or below the 14.4 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Moximed vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Moximed's grants concentrate

Moximed, Inc. is a focused PatentsView assignee: 3 CPC subclasses with 100% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). Peak complete grant year is 2015 (8 grants) versus a trough of 1 in 2022. By volume, Moximed sits between Mercari, Inc. and National University Corporation Nara Institute OF Science AND Technology.

Moximed's three-year grant acceleration

Moximed, Inc. shows 1 grants in 2022–2024 against only 10 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Mercari

39
Miltenyi Biotec

39
Mitchell Internat…

39
Mitsubishi Shindoh

39
Myfitnesspal

39
National Pingtung…

39
National Semicond…

39
National Universi…

39
Moximed ◀

39

What this shows Moximed holds 39 patents at rank #8,251, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Moximed

By rank, the assignees closest to #8,251 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in Moximed's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Moximed, neither rank-band nor same-CPC leaders (those blocks stay above). In A61B (Diagnosis), Moximed ranks #491 of 7,127 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (27 here).

Codman Neuro Sciences Sarl 27 InSyte Systems, Inc. 27 Zwilling J.A. Henckels AG 27 Kverneland A/S 27

Moximed's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

27 24th percentile higher than 24% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2022

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Moximed, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	8	20.5%
2016	6	15.4%
2017	7	17.9%
2018	7	17.9%
2019	4	10.3%
2020	6	15.4%
2022	1	2.6%

Which technologies does Moximed, Inc. patent most?

A61B - DIAGNOSIS; SURGERY; Identification 39

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 33

Y10S - Technical Subjects Covered BY Former Uspc Cross-reference ART Collections [XRACs] AND Digests 4

Top 3 of 3 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Moximed, Inc.'s patent record in context - here's where to go next.

Moximed, Inc.'s lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 100% of its portfolio - see every assignee active in that class. Explore A61B
Ranked #8,252 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Moximed, Inc. against Mercari, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 27.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.